Dr. Rongrong Li 李蓉蓉
Chief Physician
Department of Medical Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and medical treatment of digestive and urinary system tumors, including gastric cancer, colorectal cancer, and kidney cancer.
Dr. Li holds a master’s degree in medical oncology from Central South University. Since graduation, Dr. Li has worked in clinical oncology with experience in diagnosis and treatment. Dr. Li has participated in multiple projects funded by the Science and Technology Department and Health Department, as well as large domestic and international clinical drug trials, and published dozens of papers in core journals.
Professional roles
- Member, Youth Committee of the Molecular Targeted Therapy Professional Committee, Hunan Anti-Cancer Association
Name order: in Chinese the family name comes first (Li Rongrong). Papers usually list the name as Rongrong Li or Li R.
Selected publications
9 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Cancer, 2026 (first author): Fruquintinib with programmed cell death - 1 inhibitors versus triflueridine - tipiracil - 102 with bevacizumab in late-line mCRC: A retrospective cohort study based on propensity score matching. PubMed 41684147
- J Gastrointest Oncol, 2024 (first author): Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study. PubMed 38756644
- Pharm Biol, 2022 (first author): A novobiocin derivative, XN4, triggers ferroptosis in gastric cancer cells via the activation of NOX4. PubMed 35938505
- Neoplasma, 2022 (senior author): hsa_circ_0067514 suppresses gastric cancer progression and glycolysis via miR-654-3p/LATS2 axis. PubMed 35818964
- Ann Transl Med, 2022 (first author): Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study. PubMed 36111036
- Kaohsiung J Med Sci, 2021 (first author): The effects and mechanism of α-mangostin on chemosensitivity of gastric cancer cells. PubMed 34003591
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion